Human pseudomyiasis caused by Eristalis tenax (Linnaeus) (Diptera: Syrphidae) in Goiás

The objective of the present work was to register the first proven cases of human pseudomyiasis due to Eristalis tenax in Goiás State, Brazil, underscoring their clinical manifestations and direct relationship with hygiene. The taxonomic identification of the instars was done according to the descriptions and keys presented by James (1947), Hartley (1961) and Guimarães & Papavero (1999). Two cases were observed. In both cases there was no evidence of apparent mental disturbance. The clinical picture of these cases was self limited. The water supply, sewer system, socioeconomic level and habits of the suspect species of the flies are criteria that should be investigated.

Os primórdios do controle da doença de Chagas (em homenagem a Emmanuel Dias, pioneiro do controle, no centenário de seu nascimento)

Carlos Chagas se apercebe precocemente da necessidade do controle da doença, frente ao seu impacto social e grande dispersão. O vetor é o elo mais vulnerável e a melhoria da habitação a estratégia mais exeqüível. Em paralelo, há que dar-se visibilidade à doença, para justificar o controle. Como primeiras tentativas concretas, Souza Araújo pleiteará reformas de vivendas, no Paraná (1918), e Ezequiel Dias e cols ensaiarão inúmeros compostos químicos contra os triatomíneos (1921). A luta anti triatomínica será retomada por Emmanuel Dias a partir de 1944, em Bambuí, re testando compostos antigos, lança chamas e gás cianídrico. Em 1946 decepciona-se com o DDT, mas, em 1947, com Pellegrino ensaia com êxito o gammexane (BHC PM). Aliando-se a Pinotti, logo partem para ensaios de campo no Triângulo Mineiro, justificando expansão para outras áreas. A estratégia básica é a luta química continuada, em áreas endêmicas contínuas. Em 1959, Pedreira de Freitas descreve o expurgo seletivo, formatando a etapa de avaliação, da SUCEN e da futura SUCAM. Em 1975, o programa nacional é normatizado e armam-se inquéritos nacionais (triatomíneos e sorológico). Em 1979 ensaiam-se novos piretróides e em1983 o programa nacional é expandido. Estudada desde 1950 pelo grupo de Nussenzweig, em São Paulo, a transmissão transfusional mostra-se vulnerável ao controle por quimioprofilaxia e seleção sorológica de doadores, mas só se implementa, em definitivo, nos anos 1980, com a emergência da pandemia de HIV/AIDS. Praticamente desde os trabalhos pioneiros, o controle da tripanossomíase evidenciou-se eficiente, desde que continuado e sustentado por ações educativas e por decisão política.

Monitoring the treatment of sepsis with vancomycin in term newborn infants

A prospective study was conducted to determine if standardized vancomycin doses could produce adequate serum concentrations in 25 term newborn infants with sepsis. Purpose: The therapeutic response of neonatal sepsis by Staphylococcus sp. treated with vancomycin was evaluated through serum concentrations of vancomycin, serum bactericidal titers (SBT), and minimum inhibitory concentration (MIC). METHOD: Vancomycin serum concentrations were determined by the fluorescence polarization immunoassay technique , SBT by the macro-broth dilution method, and MIC by diffusion test in agar . RESULTS: Thirteen newborn infants (59.1%) had adequate peak vancomycin serum concentrations (20--40 mg/mL) and one had peak concentration with potential ototoxicity risk (>40 µg/mL). Only 48% had adequate trough concentrations (5--10 mg/mL), and seven (28%) had a potential nephrotoxicity risk (>10 µg/mL). There was no significant agreement regarding normality for peak and trough vancomycin method (McNemar test : p = 0.7905). Peak serum vancomycin concentrations were compared with the clinical evaluation (good or bad clinical evolution) of the infants, with no significant difference found (U=51.5; p=0.1947). There was also no significant difference between the patients' trough concentrations and good or bad clinical evolution (U = 77.0; p=0.1710). All Staphylococcus isolates were sensitive to vancomycin according to the MIC. Half of the patients with adequate trough SBT (1/8), also had adequate trough vancomycin concentrations and satisfactory clinical evolution. CONCLUSIONS: Recommended vancomycin schedules for term newborn infants with neonatal sepsis should be based on the weight and postconceptual age only to start antimicrobial therapy. There is no ideal pattern of vancomycin dosing; vancomycin dosages must be individualized. SBT interpretation should be made in conjunction with the patient's clinical presentation and vancomycin serum concentrations. Those laboratory and clinical data favor elucidation of the probable cause of patient's bad evolution, which would facilitate drug adjustment and reduce the risk of toxicity or failing to achieve therapeutic doses.